This has been both an exciting and a turbulent time for the global economy and the equity markets. How have chemical company shares and valuations fared in the public equity markets this year? What is driving the movement of their share prices now and in the future and are we seeing different patterns in different chemical sectors and geographies? Are we heading for another round of shareholder activist skirmishes with public chemical companies? Why are we going through a somewhat disjointed experience in terms of the chemical industry IPO experiences these last two years and what are the lessons for investors and owners of private chemical companies?

Peter Young, President of a leading chemicals and life science investment bank, Young & Partners. He will use the firm's highly regarded data analyses and the firms' experience working with clients on a global basis to answer the above and other questions about the chemical industry stock market performance, IPOs and the implications for companies and investors.

 

In addition to the featured speaker, this will be the Annual Meeting of Société de Chimie Industrielle and will include the election of officers and Board Members, as well as a brief review of Société de Chimie Industrielle's year.

About our Speaker:
Peter Young is President of Young & Partners, a leading independent leading chemicals and life science investment banks. Mr. Young has been a long-term board member and officer of Société and has been involved in investment banking for the chemical and life science industries for over thirty years as the head of Young & Partners and, previously, as the head of the global chemical groups of Lehman, Schroders and Salomon Brothers. Prior to becoming an investment banker, he advised chemical and pharmaceutical companies while with Bain & Co. and was in private equity with J.H. Whitney & Co. He is a graduate of Harvard Business School (MBA), New York University (MS) and Yale (BA). He is a CPA and on the board of the Chemical Heritage Foundation and the Editorial Advisory Board of Pharmaceutical Executive.
 
Young & Partners is a focused chemical and life science industry investment bank serving the M&A, financing and financial advisory needs of clients in North America, Europe, Asia and South America. 55% of its projects are outside North American and 75% are cross border. The firm focuses is on providing exceptional investment banking services, in-depth industry expertise, the benefit of broad industry contacts, and senior attention to every transaction without any conflicts of interest. They have successfully completed a large number of investment banking projects for companies around the world over the last 22 years. Their website is www.youngandpartners.com.